dm+d

Unassigned

New Medicines

Amyotrophic lateral sclerosis (motor neurone disease)

Information

New molecular entity
Orion Pharma
Orion Pharma

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Jul 20Development discontinued as pre-specified endpoints were not met in the trial [7].

Category

Calcium sensitizer: increases force of contraction of cardiac and skeletal muscle by binding to troponin C.
ALS is the most common form of motor neurone disease; annual incidence of about 2 cases per 100,000 population and prevalence is about 5-7 per 100,000 [1].
Amyotrophic lateral sclerosis (motor neurone disease)
Oral